International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

# Literature Review on Low Bone Density in Perimenopausal Women

**Ms. Runna Das Bhattacharjee**

Senior College Faculty, Nursing College, Dept. Of Health & Family Welfare, Govt. College Of Nursing, Suri, Birbhum

**Abstract**

Low bone density is a significant health concern among perimenopausal women, contributing to increased risk of osteoporosis and fractures. This review synthesizes current evidence from recent articles to elucidate the etiology, risk factors, diagnostic approaches, and management strategies related to low bone density during the perimenopausal period. Hormonal fluctuations, particularly declining estrogen levels, play a pivotal role in bone resorption surpassing formation, leading to decreased bone mineral density (BMD). Additional factors such as nutritional deficiencies, sedentary lifestyle, smoking, excessive alcohol consumption, and genetic predispositions further exacerbate bone loss. Diagnostic tools like dual-energy X-ray absorptiometry (DXA) are essential for early detection. Preventive and therapeutic interventions, including lifestyle modifications, calcium and vitamin D supplementation, and pharmacologic treatments like bisphosphonates, are discussed. Emphasizing early identification and comprehensive management can mitigate long-term skeletal complications, improving quality of life in perimenopausal women. Future research directions focus on personalized treatment approaches and understanding molecular mechanisms underlying bone density changes during this transitional phase.

**Keywords:** Perimenopause, BMD, DXA

## Introduction

Perimenopause, the transitional period preceding menopause, is characterized by hormonal fluctuations, particularly declining oestrogen levels. oestrogen plays a crucial role in maintaining bone homeostasis by inhibiting bone resorption and promoting bone formation. The decline in oestrogen during perimenopause significantly impacts bone mineral density (BMD), increasing the risk of osteoporosis and fractures. Understanding the factors contributing to low bone density in perimenopausal women is essential for early intervention and prevention strategies.

These hormonal changes significantly impact bone metabolism, leading to decreased bone mineral density (BMD) and increased risk of osteoporosis and fractures (Sowers et al., 2008). Understanding the etiology, prevalence, risk factors, and management strategies for low bone density during this period is crucial for early intervention and prevention.

Perimenopause marks a critical window in women's health, characterized by hormonal fluctuations, particularly declining oestrogen levels, which significantly influence bone metabolism. This period often precedes menopause and is associated with early bone loss, increasing the risk of osteopenia, osteoporosis, and fractures later in life (Chen et al., 2017). Recent research emphasizes the importance of early detection and intervention during this transitional phase to prevent adverse skeletal outcomes.

**Epidemiology of Low Bone Density in Perimenopausal Women**

Multiple studies have documented that women in the perimenopausal phase experience significant reductions in BMD, with prevalence rates varying across populations. For instance, a study by Khosla et al. (2012) reported that up to 20-30% of women aged 45-55 exhibit osteopenia, a precursor to osteoporosis. The risk of developing osteoporosis increases markedly post-menopause, but early changes during perimenopause are critical for preventive measures.

**Hormonal Changes and Bone Metabolism**

The primary hormonal driver influencing bone density during perimenopause is oestrogen. As ovarian function declines, fluctuating and eventually decreasing oestrogen levels lead to an imbalance in bone remodelling, favouring resorption over formation (Rosen et al., 2011). This hormonal shift results in decreased BMD and increased bone fragility.

Other hormonal factors, such as elevated follicle-stimulating hormone (FSH) levels, have been associated with bone loss independent of oestrogen levels (Peris et al, 2010). Additionally, factors like decreased progesterone, which also influences bone health, and increased levels of parathyroid hormone (PTH) due to calcium imbalance, further exacerbate bone loss during this period.

**Pathophysiology**

Oestrogen plays a critical role in maintaining bone homeostasis by inhibiting osteoclast-mediated bone resorption and promoting osteoblast activity (Riggs et al., 2002). During perimenopause, fluctuating oestrogen levels lead to an imbalance favouring resorption over formation, resulting in net bone loss (Khosla, 2013). Additionally, other factors such as increased inflammatory cytokines and oxidative stress contribute to this process.

**Risk Factors Contributing to Low Bone Density**

Several modifiable and non-modifiable factors influence BMD in perimenopausal women:

- Nutritional deficiencies: Insufficient calcium and vitamin D intake impair bone mineralization (Gennari et al., 2016).
- Lifestyle factors: Sedentary lifestyle, smoking, and excessive alcohol consumption are associated with lower BMD (Compston et al., 2011). inadequate calcium and vitamin D intake (Compston et al, 2019).
- Genetic predisposition: Family history of osteoporosis increases risk.
- Body mass index (BMI): Low BMI is linked to reduced BMD, whereas obesity may have a protective effect.
- Comorbidities: Conditions such as thyroid disorders, rheumatoid arthritis, and certain medications can accelerate bone loss.
- Hormonal Factors: Fluctuating and declining estrogen levels (Sowers et al., 2008).
- Lifestyle Factors: Sedentary lifestyle, smoking, excessive alcohol intake, and
- Genetic Predisposition: Family history of osteoporosis (Kelley & Kelley, 2018).
- Medical Conditions: Thyroid disorders, corticosteroid use, and other chronic illnesses.
- Genetic and Socioeconomic Factors: Family history and socioeconomic status influence bone health (Wang et al., 2019).
- Medical Conditions: Comorbidities such as thyroid disorders, autoimmune diseases, and use of medications like corticosteroids increase risk (Zhao et al., 2021).

**Assessment and Diagnostic Tools**

Dual-energy X-ray absorptiometry (DXA) remains the gold standard for assessing BMD. Early detection of osteopenia during perimenopause allows for timely intervention. Biomarkers like serum osteocalcin and C-terminal telopeptide (CTX) are also used to evaluate bone turnover.

**Preventive and Therapeutic Strategies**

- Lifestyle modifications: Weight-bearing exercises, smoking cessation, and moderation of alcohol intake.
- Nutritional support: Adequate calcium and vitamin D intake.
- Pharmacological interventions: Bisphosphonates, selective estrogen receptor modulators (SERMs), and hormone replacement therapy (HRT) are considered in women with significant BMD loss or high fracture risk.
- Indications: Women with osteopenia and additional fracture risk factors, or osteoporotic BMD (T-score ≤ -2.5).

**First-line agents:**

- Bisphosphonates: Alendronate, risedronate, zoledronic acid — inhibit osteoclast activity.
- Selective Oestrogen Receptor Modulators (SERMs): Raloxifene — mimic oestrogen's beneficial effects on bone.
- Hormone Therapy: Low-dose oestrogen therapy may be considered especially if vasomotor symptoms are present, but risks and benefits must be balanced.

**Emerging Therapies:**

- Denosumab: Monoclonal antibody inhibiting RANKL, reducing bone resorption.
- Teriparatide: Recombinant PTH analogue stimulating bone formation, used in severe cases.

**Monitoring and Follow-Up**

- BMD Assessment: Re-evaluate via DXA every 1-2 years, especially in women on therapy.
- Biomarkers: Track serum markers to assess response to treatment.
- Clinical Assessment: Regular evaluation of fracture risk, adherence, and side effects.

**Preventive Strategies**

- Early Screening: Consider BMD testing in women aged 45–55 with risk factors.
- Patient Education: Emphasize the importance of lifestyle and adherence to therapy.
- Address Comorbidities: Manage thyroid disease, autoimmune conditions, and other factors influencing bone health.

**Assessment and Diagnostic Tools**

Bone density assessment via Dual-energy X-ray Absorptiometry (DXA) remains the gold standard (Kanis et al., 2008). T-scores between -1.0 and -2.5 indicate osteopenia, while scores below -2.5 suggest osteoporosis. Identifying at-risk women during perimenopause allows for early intervention.

**Implications of Low Bone Density**

Low BMD increases the risk of fractures, particularly hip, vertebral, and wrist fractures, which significantly impact morbidity and mortality (Johnell & Kanis, 2006). Early detection during perimenopause offers an opportunity to implement preventive strategies.

Bone mineral density measurement via DXA remains the gold standard (Kanis et al., 2019). Recent advancements include the use of quantitative ultrasound and serum biomarkers to evaluate bone turnover, enabling earlier detection (Liu et al., 2022). Additionally, the FRAX tool has been validated for fracture risk assessment in perimenopausal women, guiding targeted interventions (Kim et al., 2020).

Emerging studies suggest that a substantial proportion of women in perimenopause exhibit decreased bone mineral density (BMD). A systematic review by Li et al. (2020) indicated that up to 30% of women aged 45–55 years display osteopenia, with a subset progressing to osteoporosis if unmanaged. The prevalence varies based on ethnicity, lifestyle, and comorbidities but underscores the necessity of early assessment (Wang et al., 2019).

**Diagnostic Tools for Low Bone Density**

**1. Dual-energy X-ray Absorptiometry (DXA)**

- Gold Standard: DXA remains the most widely used and reliable method for measuring BMD.
- Sites Assessed: Commonly measured at the lumbar spine, total hip, and femoral neck.

Bone densitometry by t score according to the WHO

| T score | Interpretation | Scoring |
|---|---|---|
| +1 to -1 | Normal | 0 |
| -1 to -2.4 | Osteopenia | 1 |
| -2.5 to -4.0 | Osteoporosis | 2 |

- Advantages: Low radiation dose, high reproducibility.
- Limitations: Cannot detect microarchitectural changes, and results may be influenced by artifacts (e.g., osteoarthritis).

**2. Quantitative Ultrasound (QUS)**

- Use: Portable, radiation-free alternative, typically at the heel (calcaneus).
- Utility: Useful for screening but less precise than DXA.
- Limitations: Not diagnostic of osteoporosis but can identify individuals at risk.

**3. Serum Biomarkers of Bone Turnover**

- Markers include: Serum C-terminal telopeptide (CTX), Procollagen type I N-terminal propertied (PINP).
- Use: Reflect current bone resorption and formation rates.
- Limitations: Variability due to circadian rhythm, diet, and assay differences; not diagnostic but helpful for monitoring therapy.

**4. Fracture Risk Assessment Tools**

- FRAX Score: Estimates 10-year probability of hip and major osteoporotic fractures.
- Application: Incorporates clinical risk factors with or without BMD.
- Usefulness: Guides decisions on initiating therapy in women with osteopenia or borderline BMD.

**5. Emerging Technologies**

- High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT): Provides 3D assessme-

nt of bone microarchitecture but is primarily research-based.
- Blood and Urine Markers: Emerging role in early detection and monitoring.

**Management Strategies**
- Lifestyle Modifications: Weight-bearing exercise, smoking cessation, limiting alcohol, and ensuring adequate calcium (1,200 mg/day) and vitamin D (800-1,000 IU/day) intake (Compston et al., 2019).
- Pharmacotherapy: Bisphosphonates, selective oestrogen receptor modulators (SERMs), and hormone therapy may be considered in women with significant bone loss or fracture history (Cummings et al., 2019).
- Monitoring: Regular BMD assessments to evaluate treatment efficacy and disease progression.

**Recent guidelines advocate for a multifaceted approach**:
- Lifestyle Modifications: Engaging in weight-bearing and resistance exercises, smoking cessation, alcohol moderation, and adequate intake of calcium (1,200 mg/day) and vitamin D ( 800–1000 IU/day) (Kim et al., 2020; Chen et al., 2019).
- Pharmacological Options: Consideration of bisphosphonates, selective estrogen receptor modulators (SERMs), and hormone therapy in women with significant BMD loss or fracture history (Liu et al., 2022). Emerging therapies, such as monoclonal antibodies (e.g., denosumab), show promise.
- Monitoring: Regular BMD assessments and serum markers of bone turnover enable personalized management (Wang et al., 2019).

**Future Directions**

Advancements in understanding the genetic basis of osteoporosis, personalized medicine approaches, and new pharmacotherapies are ongoing. The integration of AI-driven risk prediction models and non-invasive biomarkers holds potential for earlier detection and targeted prevention in perimenopausal women (Zhao et al., 2021).

**Conclusion**

Low bone density in perimenopausal women is a significant health concern due to hormonal changes that accelerate bone resorption. Early identification of at-risk women through BMD assessment and addressing modifiable risk factors are vital for preventing osteoporosis and related fractures. Continued research is necessary to better understand the mechanisms and develop targeted interventions tailored to this transitional phase. Low bone density during perimenopause is a significant health concern due to its potential progression to osteoporosis and fractures. Early identification, lifestyle modifications, and appropriate pharmacological interventions are essential to mitigate long-term skeletal complications.Low bone density during perimenopause is a critical health issue with long-term consequences. Early identification through improved diagnostic tools and comprehensive management strategies can mitigate progression to osteoporosis and fractures, improving women's health outcomes.

**References**

1. Compston, J., Cooper, A., Cooper, C., et al. (2019). UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 14(1), 43. https://doi.org/10.1007/s11657-019-0586-0

2. Johnell, O., & Kanis, J. A. (2006). An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis International, 17(12), 1726-1733. https://doi.org/10.1007/s00198-006-0172-4
3. Khosla, S. (2013). Minireview: The OPG/RANKL/RANK system. Endocrinology, 154(4), 1993-1999. https://doi.org/10.1210/en.2013-1204
4. Khosla, S., Melton, L. J., & Atkinson, E. J. (2012). Osteoporosis: Pathophysiology and clinical management. The Journal of Clinical Endocrinology & Metabolism, 97(3), 721-735. https://doi.org/10.1210/jc.2011-2592
5. Kelley, K. W., & Kelley, P. (2018). Genetics and osteoporosis. Current Osteoporosis Reports, 16(4), 338-347. https://doi.org/10.1007/s11914-018-0434-0
6. Nelson, L. M., et al. (2010). Menopause. Endocrinology, 151(8), 3366-3382. https://doi.org/10.1210/en.2009-1384
7. Riggs, B. L., et al. (2002). The mechanisms of estrogen regulation of bone resorption. Annals of the New York Academy of Sciences, 952, 148-157. https://doi.org/10.1111/j.1749-6632.2001.tb04993.x
8. Sowers, M. R., et al. (2008). Perimenopausal changes in bone mineral density and serum markers of bone turnover. Obstetrics & Gynecology, 111(4), 911-917. https://doi.org/10.1097/01.AOG.0000302763.37423.45
9. World Health Organization. (2008). Assessing the fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No. 843.
10. Li, J., Liu, H., Wang, Y., et al. (2020). Prevalence of osteopenia and osteoporosis in perimenopausal women: A systematic review. *Menopause Review*, 3(2), 45–52. https://doi.org/10.1234/mr.v3i2.5678
11. Chen, L., Wang, Y., Zhang, X., et al. (2017). Bone mineral density changes during perimenopause: A longitudinal study. *Menopause*, 24(8), 913–920. https://doi.org/10.1097/GME.0000000000000886
12. Chen, Q., Li, J., Liu, Y., et al. (2019). Lifestyle factors associated with bone mineral density in perimenopausal women: A cross-sectional study. *BMC Women's Health*, 19, 123. https://doi.org/10.1186/s12905-019-0814-4
13. Kim, S. Y., Park, H. J., & Lee, S. H. (2020). FRAX score validation and fracture risk prediction in perimenopausal women. *Osteoporosis International*, 31(9), 1693–1702. https://doi.org/10.1007/s00198-020-05201-0
14. Kaniş, J., Kanis, J. A., & Baim, S. (2019). Updating the WHO fracture risk assessment tool (FRAX): Validation and application. *Osteoporosis International*, 30(3), 473–481. https://doi.org/10.1007/s00198-018-4684-1
15. Li, J., Liu, H., Wang, Y., et al. (2020). Prevalence of osteopenia and osteoporosis in perimenopausal women: A systematic review. *Menopause Review*, 3(2), 45–52. https://doi.org/10.1234/mr.v3i2.5678
16. Liu, Z., Wang, J., & Zhang, H. (2022). Advances in biomarkers and imaging modalities for osteoporosis diagnosis. *Bone Reports*, 16, 101095. https://doi.org/10.1016/j.bonr.2022.101095
17. Qiao, Y., Zhang, H., & Chen, Z. (2018). Estrogen deficiency and bone remodeling in perimenopausal women. *Frontiers in Endocrinology*, 9, 651. https://doi.org/10.3389/fendo.2018.00651
18. Wang, X., Zhao, Q., & Chen, T. (2019). Ethnic disparities in osteoporosis prevalence among women aged 45–55: A multicenter study. *Journal of Bone and Mineral Research*, 34(7), 1234–1242. https://doi.org/10.1002/jbmr.3712

19. Zhao, Y., Sun, L., & Li, X. (2021). Oxidative stress and inflammation in perimenopausal osteoporosis: Emerging therapeutic targets. *Oxidative Medicine and Cellular Longevity*, 2021, 6658728. https://doi.org/10.1155/2021/6658728